febridx
rapid
pointofcar
diagnost
test
design
aid
differenti
bacteri
viral
acut
respiratori
infect
ari
thu
help
guid
decis
regard
prescript
antibiot
outpati
set
febridx
carri
ce
mark
use
eu
also
approv
sever
countri
includ
canada
saudi
arabia
singapor
indic
use
patient
year
old
symptom
consist
communityacquir
ari
test
involv
use
immunoassay
fingerstick
blood
sampl
provid
simultan
qualit
measur
elev
level
creactiv
protein
crp
myxoviru
resist
protein
mxa
two
prospect
multicentr
studi
patient
acut
upper
respiratori
tract
infect
febridx
shown
sensit
specif
identifi
patient
clinic
signific
infect
differenti
infect
bacteri
viral
aetiolog
test
simpl
requir
addit
equip
produc
action
result
min
demonstr
small
retrospect
analysi
febridx
result
help
guid
improv
antibiot
prescrib
decis
reduc
unnecessari
inappropri
prescript
antibiot
ari
probabl
viral
aetiolog
import
antibiot
stewardship
also
reduc
unnecessari
exposur
patient
risk
antibioticrel
advers
event
febridx
thu
repres
use
diagnost
tool
outpati
set
simpl
allinon
diagnost
test
assist
diagnosi
bacteri
viral
ari
measur
host
respons
infect
base
rapid
immunoassay
provid
simultan
qualit
measur
elev
level
crp
mxa
sensit
specif
identifi
patient
clinic
signific
infect
differenti
infect
bacteri
viral
aetiolog
produc
action
result
min
use
help
guid
antibiot
prescrib
decis
turer
febridx
also
offer
opportun
review
articl
chang
result
comment
receiv
made
basi
scientif
editori
merit
acut
respiratori
infect
ari
viral
bacteri
one
common
reason
visit
primari
urgent
care
clinic
given
overlap
profil
sign
symptom
distinguish
ari
bacteri
viral
aetiolog
clinic
challeng
clinic
uncertainti
regard
infect
aetiolog
along
factor
eg
patient
parent
pressur
expect
frequent
result
prescript
antibiot
infect
probabl
viral
aetiolog
despit
like
benefit
unnecessari
inappropri
prescript
antibiot
broad
neg
consequ
includ
contribut
rise
spread
antimicrobi
resist
consid
one
biggest
threat
global
health
unnecessarili
expos
patient
risk
advers
event
includ
lifethreaten
event
eg
anaphylaxi
stevensjohnson
syndrom
clostridium
difficil
infect
well
neg
affect
patient
health
care
individu
popul
level
effect
also
associ
signific
econom
cost
sensit
specif
diagnost
tool
aid
diagnosi
ari
particularli
differenti
bacteri
viral
infect
primari
urgent
healthcar
set
lack
avail
method
standalon
creactiv
protein
crp
measur
procalcitonin
measur
molecular
eg
rapid
antigen
detect
test
pcr
cultur
method
limit
issu
includ
insuffici
sensit
andor
specif
includ
inabl
distinguish
colon
true
infect
excess
time
result
provid
action
data
poor
reproduc
andor
requir
special
potenti
costli
equip
febridx
rapid
pointofcar
diagnost
test
design
aid
differenti
bacteri
viral
ari
object
help
reduc
inappropri
prescript
antibiot
ari
viral
aetiolog
test
carri
ce
mark
undergo
fda
trial
approv
involv
use
immunoassay
fingerstick
blood
sampl
provid
simultan
qualit
measur
crp
myxoviru
resist
protein
mxa
togeth
use
conjunct
clinic
assess
identifi
patient
clinic
signific
infect
distinguish
infect
bacteri
viral
aetiolog
articl
review
febridx
test
technolog
clinic
perform
util
intend
use
ce
mark
base
avail
data
febridx
carri
ce
mark
approv
use
eu
countri
recogn
mark
febridx
also
commerci
avail
australia
canada
singapor
countri
gulf
cooper
council
bahrain
kuwait
oman
qatar
saudi
arabia
unit
arab
emir
febridx
intend
use
medic
profession
outpati
set
ie
primari
caregener
practition
well
urgent
careoutofhour
medic
centr
pharmaci
emerg
depart
test
indic
use
aid
diagnosi
ari
patient
year
old
present
within
day
acuteonset
fever
within
day
new
onset
respiratori
symptom
consist
communityacquir
ari
includ
possibl
cough
andor
acut
bronchiti
specif
febridx
design
use
differenti
viral
influenza
ab
adenoviru
respiratori
syncyti
viru
metapneumoviru
parainfluenza
viru
epsteinbarr
viru
bacteri
ari
neg
febridx
test
result
preclud
respiratori
infect
eg
one
caus
rhinoviru
coronaviru
test
use
conjunct
clinic
evid
includ
laboratori
radiograph
epidemiolog
inform
febridx
test
immunoassay
util
simultan
qualit
measur
crp
mxa
peripher
whole
blood
crp
nonspecif
acutephas
protein
serv
sensit
earli
marker
inflamm
tissu
injuri
infect
crp
level
becom
markedli
elev
presenc
clinic
signific
acut
bacteri
infect
crp
measur
play
role
diagnosi
infect
howev
crp
consid
suffici
specif
marker
differenti
bacteri
viral
infect
mxa
intracellular
gtpase
protein
induc
type
type
iii
interferon
serv
sensit
specif
marker
viral
infect
mxa
antivir
activ
broad
rang
pathogen
virus
interferon
product
respons
viral
infect
lead
increas
mxa
level
rational
behind
febridx
test
measur
crp
mxa
togeth
combin
sensit
crp
specif
mxa
use
togeth
rapid
pointofcar
test
marker
serv
aid
differenti
viral
bacteri
ari
allinon
singleus
dispos
febridx
test
devic
consist
later
flow
test
strip
togeth
builtin
safeti
lancet
blood
collect
tube
buffer
deliveri
system
contain
plastic
hous
unit
test
strip
contain
two
result
line
one
crp
one
mxa
monoclon
anticrp
antimxa
antibodi
respect
control
line
febridx
test
produc
visual
qualit
resultsif
serum
level
crp
andor
mxa
meet
cutoff
level
ie
mgl
crp
ngml
mxa
correspond
posit
line
appear
result
window
cutoff
level
select
optim
sensit
specif
combin
differenti
viral
bacteri
ari
wherea
patient
ari
symptom
crp
level
mgl
like
nonbacteri
selflimit
infect
crp
level
mgl
associ
clinic
signific
immun
respons
mxa
level
ngml
establish
sensit
cutoff
identifi
viral
infect
febridx
test
procedur
simpl
rapid
typic
perform
briefli
fingertip
lanc
use
builtin
lancet
blood
sampl
drawn
blood
collect
tube
capillari
action
deliv
via
blood
transfer
zone
test
strip
test
activ
buffer
solut
deliv
press
buffer
releas
button
result
read
min
clinic
perform
febridx
test
evalu
two
prospect
multicentr
clinic
trial
use
conveni
sampl
patient
enrol
clinic
site
usa
studi
enrol
patient
adult
children
age
year
clinic
sign
symptom
acut
upper
respiratori
tract
infect
includ
new
onset
cough
sore
throat
within
past
day
histori
fever
within
past
day
patient
suspect
lower
respiratori
tract
infect
acut
bronchiti
exclud
among
enrol
patient
two
studi
patient
patient
age
year
studi
patient
underw
test
febridx
panel
refer
diagnost
test
design
identifi
patient
clinic
signific
ari
differenti
bacteri
viral
aetiolog
refer
diagnost
test
includ
standard
microbiolog
test
eg
bacteri
cultur
pcr
viral
atyp
bacteri
pathogen
detect
bacteri
andor
viral
pathogen
presenc
laboratori
test
eg
white
blood
cell
count
includ
check
lymphocytosi
bandaemia
measur
serum
procalcitonin
level
epsteinbarr
viru
serolog
identifi
host
immun
respons
algorithm
base
refer
test
data
use
classifi
patient
febridx
test
refer
test
algorithm
patient
classifi
bacteri
ari
viral
ari
neg
clinic
signific
ari
addit
panel
two
physician
expertis
respiratori
infect
blind
febridx
test
result
review
individu
patient
case
report
togeth
refer
test
result
could
overrul
refer
test
algorithm
classif
give
final
refer
classif
refer
algorithm
classifi
patient
two
studi
bacteri
viral
neg
studi
strong
agreement
physician
panel
algorithm
classif
two
patient
first
studi
one
patient
second
studi
classifi
neg
refer
algorithm
reclassifi
physician
panel
bacteri
base
febridx
test
result
patient
two
studi
classifi
bacteri
viral
neg
febridx
test
demonstr
high
degre
diagnost
accuraci
identifi
patient
clinic
signific
bacteri
viral
ari
tabl
classifi
result
bacteri
versu
bacteri
overal
agreement
febridx
result
refer
standard
result
physician
overrid
studi
classifi
result
viral
versu
viral
overal
agreement
across
studi
bacteri
infect
sensit
specif
respect
viral
sensit
specif
respect
tabl
note
accuraci
febridx
diagnos
bacteri
infect
enhanc
patient
confirm
fever
time
enrol
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
studi
higher
among
patient
compar
overal
studi
popul
tabl
test
febridx
specif
one
studi
also
includ
asymptomat
control
popul
n
total
analys
age
year
conveni
sampl
subject
without
sign
symptom
infect
among
asymptomat
control
popul
subject
neg
febridx
test
result
give
test
specif
ci
two
fals
posit
febridx
test
result
one
viral
one
bacteri
confirm
elisa
test
accur
measur
mxa
crp
respect
addit
one
subject
test
febridx
neg
found
elev
crp
level
evid
clinic
util
febridx
avail
retrospect
chart
review
analysi
involv
patient
administ
febridx
test
present
outpati
gener
practic
symptom
ari
patient
singl
practic
uk
mean
age
year
rang
year
analysi
involv
chart
review
patient
suspect
clinic
diagnosi
febridx
test
result
antibiot
prescript
includ
possibl
manag
alter
respons
therapi
patient
outcom
base
analysi
febridx
test
alter
clinic
manag
case
includ
eight
case
antibiot
withheld
febridx
test
indic
viral
infect
six
case
neg
result
two
case
clinic
diagnosi
possibl
bacteri
infect
two
case
antibiot
prescrib
febridx
test
indic
bacteri
infect
clinic
diagnosi
probabl
viral
infect
one
two
patient
subsequ
diagnos
bacteri
sepsi
hospit
addit
two
higherrisk
patient
patient
sudden
physic
deterior
immunocompromis
patient
prescrib
antibiot
despit
neg
febridx
test
result
patient
analysi
achiev
full
clinic
recoveri
exclud
patient
diagnos
bacteri
sepsi
test
posit
bacteri
infect
febridx
patient
experienc
clinic
complic
requir
unschedul
medic
consult
advanc
diagnost
test
identifi
key
area
potenti
aid
antibiot
stewardship
effort
ari
account
larg
proport
antibiot
prescript
outpati
set
howev
method
differenti
ari
viral
bacteri
aetiolog
thu
identifi
patient
may
benefit
antibiot
limit
issu
includ
insuffici
accuraci
excess
time
action
result
andor
requir
special
equip
expertis
uk
nation
institut
health
care
excel
nice
guidelin
diagnosi
manag
pneumonia
recommend
pointofcar
crp
test
consid
patient
present
symptom
lower
respiratori
tract
infect
clinic
assess
uncertain
whether
antibiot
prescrib
qualit
febridx
test
measur
elev
level
crp
simultan
measur
elev
level
viral
infect
marker
mxa
togeth
simpl
rapid
allinon
pointofcar
test
sect
use
two
marker
febridx
combin
sensit
crp
specif
mxa
combin
use
distinguish
viral
bacteri
ari
inde
clinic
perform
febridx
test
identifi
patient
bacteri
ari
outpati
set
favour
compar
standalon
crp
mgl
procalcitonin
ngml
qualit
measur
furthermor
indirect
comparison
diagnost
assay
use
combin
crp
tumour
necrosi
factorrel
apoptosisinduc
ligand
trail
interferon
gamma
induc
measur
febridx
appear
similar
clinic
perform
advantag
greater
eas
use
rapid
action
result
anoth
benefit
febridx
test
unlik
pathogenspecif
diagnost
tool
eg
pathogenspecif
pcrbase
method
measur
crp
mxa
compon
bodi
immun
respons
enabl
febridx
distinguish
infect
presenc
pathogen
carriercolon
state
base
two
prospect
multicentr
studi
patient
ari
predominantli
upper
respiratori
tract
infect
includ
patient
acut
bronchiti
febridx
shown
sensit
specif
differenti
infect
viral
bacteri
aetiolog
sect
note
accuraci
test
appear
highest
use
patient
confirm
fever
time
test
febridx
abl
identifi
patient
viral
bacteri
coinfect
host
respons
infect
howev
case
appear
rare
sect
defin
presenc
viral
bacteri
pathogen
confirm
pcr
andor
bacteri
cultur
togeth
host
respons
inclus
elev
procalcitonin
ngml
andor
white
blood
cell
count
viral
bacteri
coinfect
observ
two
key
trial
importantli
febridx
test
shown
rule
presenc
clinic
signific
bacteri
infect
high
degre
accuraci
npv
bacteri
infect
studi
patient
confirm
fever
enrol
suggest
febridx
use
support
use
watch
wait
strategi
appropri
case
two
trial
gener
well
design
howev
limit
data
notabl
rel
low
proport
paediatr
patient
age
year
includ
trial
overal
given
paediatr
patient
compos
larg
proport
primari
care
visit
ari
evalu
clinic
perform
febridx
paediatr
patient
would
strong
interest
anoth
limit
avail
data
due
practic
constraint
studi
popul
key
trial
conveni
sampl
rather
consecut
elig
patient
potenti
could
result
sampl
bia
complementari
data
regard
clinic
perform
febridx
evid
clinic
util
febridx
reduc
unnecessari
inappropri
prescript
antibiot
sect
besid
high
level
accuraci
anoth
key
benefit
febridx
abil
provid
rapid
action
result
pointofcar
use
aid
clinic
manag
decis
base
small
retrospect
outcom
analysi
use
febridx
result
reduct
unnecessari
antibiot
prescript
subsequ
testingrel
advers
event
observ
sect
accept
limit
small
retrospect
studi
involv
patient
singl
practic
uk
analysi
demonstr
potenti
util
febridx
improv
clinic
manag
patient
ari
clinic
uncertainti
lead
unnecessari
inappropri
prescript
antibiot
ari
selflimit
andor
like
viral
aetiolog
use
accur
diagnost
test
pointofcar
complement
clinic
judgement
may
give
clinician
confid
follow
watch
wait
strategi
appropri
identifi
low
likelihood
bacteri
infect
furthermor
avail
clear
simpl
visual
result
febridx
produc
could
potenti
use
allevi
patient
parent
pressur
prescrib
antibiot
consid
necessari
anoth
aspect
clinic
util
febridx
potenti
reduct
unnecessari
antibiot
reduc
occurr
antibioticrel
advers
event
import
factor
toward
determin
util
febridx
outpati
set
costeffect
test
cost
test
could
offset
least
partial
save
cost
reduc
unnecessari
prescript
reduct
medic
consult
treatment
antibioticrel
advers
event
could
result
signific
cost
save
furthermor
effect
antibiot
resist
issu
estim
cost
billion
dollar
per
year
global
highlight
import
antibiot
stewardship
effort
econom
point
view
conclus
febridx
repres
sensit
specif
diagnost
tool
aid
differenti
viral
bacteri
ari
benefit
provid
rapid
action
result
pointofcar
test
simpletous
allinon
devic
requir
addit
equip
evalu
accuraci
test
paediatr
patient
costeffect
data
would
interest
howev
current
avail
data
suggest
febridx
valuabl
tool
aid
diagnosi
ari
outpati
set
includ
use
identif
patient
might
benefit
antibiot
duplic
remov
exclud
initi
screen
eg
press
releas
news
report
relev
drugind
preclin
studi
review
case
report
random
trial
exclud
write
eg
review
duplic
data
small
patient
number
nonrandomizedphas
iii
trial
